A Colao, University of Naples Federico II, Italy

Somatostatin analogues are the mainstay of medical therapy for patients with acromegaly. However, some patients achieve inadequate control of their disease with conventional doses of octreotide LAR or lanreotide Autogel.

A Phase III, multicenter, randomised, parallel-group, three-arm, 24-week study is planned to assess the efficacy of pasireotide LAR (40 mg), a multi-receptor targeted somatostatin analogue with high affinity for somatostatin receptor subtypes 1, 2, 3 and 5, as an alternative treatment for these patients. Data from this study is expected to be available sometime next year.